To quantify long-term effects of antihypertensive drug treatment on overall mortality and cardiovascular-specific morbidity and mortality in older people with mild to moderate systolic or diastolic hypertension and in older people with isolated systolic hypertension.
( Ն 60) assessing efficacy of antihypertensive drug therapy and providing morbidity and mortality data were sought by electronic search of register of the Blood Pressure-Lowering Treatment Trialists' Collaboration of the World Health Organization International Society of Hypertension (August 1997), The Cochrane Library (1997; Issue 1), MED-LINE (1966 to April 1997), and two Japanese databases (JMEDICINE, 1981 -1995 , and JAPIC-DOC, 1973 -1995 ; references from reviews, trials, and 10 previously published meta-analyses; and experts. STUDY SELECTION CRITERIA: Only randomized controlled trials of at least 1 year's duration providing morbidity and mortality data were acceptable for review. Trials must have included a control group that received a placebo, no hypertension therapy, or nonspecific antihypertensive therapy from their personal physician. Trials that compared two specific antihypertensives were excluded.
Trials must have been limited to persons aged 60 and older or separately reported data on subgroups of persons aged 60 and older. Participants must have had hypertension defined as systolic blood pressure of at least 140 mmHg or diastolic blood pressure of at least 90 mmHg.
Outcome measures that were assessed in the study were total mortality, including death from all causes; cardiovascular (coronary heart disease and cerebrovascular) morbidity and mortality; and dropout rates due to side effects of treatment.
DATA EXTRACTION AND ANALYSIS:
This review of 15 randomized controlled trials with 21,908 older subjects is based on two previously published meta-analyses. 5, 6 These meta-analyses employed similar data abstraction techniques: development of a standard data abstraction form, dual abstraction of data from the original reports of trial results byt wo independent reviewers, and disagreements resolved by discussion. A fifth reviewer compared the published results of these two meta-analyses.
A quality-scoring scheme was not used; instead, key trial characteristics were detailed in tabular form. Potential parameters of methodological quality listed in the table include whether randomization was completed in an appropriate and blinded manner; whether patients, providers, and outcome assessors were blinded to assigned therapy; whether the control group received a placebo; percentage of participants who did not complete follow-up (dropouts); and percentage of participants not on assigned active or placebo therapy at study completion (cross-over).
Quantitative analyses of outcomes were based on "intention to treat." The measure of effect for each study was the odds ratio. Approximate chi-square tests for heterogeneity were used to assess outcome data for compatibility, with assumption of a uniform odds ratio ( P Ͼ .10). For the sake of consistency across outcomes, a random effects model was used to combine outcomes across studies. Odds ratios were calculated as weighted averages of the log odds ratios for each study.
As further tests of sensitivity, trials that were not blinded and placebo controlled were analyzed separately from blinded (subject and provider) placebo-controlled trials. Results were also analyzed with and without those trials restricted to persons who had previously suffered a stroke. Result of trials restricted to persons with isolated systolic hypertension was analyzed as a separate group and combined with trials also assessing persons with essential hypertension. Random effects regression model was used to examine sources of heterogeneity with respect to cardiovascular morbidity and mortality, the only outcome found to be heterogenous. Smooth variance estimate was used for the log odds ratio to reduce the bias associated with the natural correlation between the log odds ratio and its variance.
MAIN RESULTS:
Fifteen trials including 21,908 older subjects were identified. The average prevalence of cardiovascular risk factors, cardiovascular disease, and competing comorbid diseases was lower in trial participants than in the general population of hypertensive older persons. Most subjects were aged 60 to 80. Most trials were conducted in Western industrialized countries and evaluated diuretic and beta-blocker therapies. Based on this review, treatment of the young old and middle old clearly decreases overall morbidity and mortality over 5 years, with the number needed to treat as follows. One in 19 treated patients could be saved from a cardiovascular morbidity and mortality event (95% confidence interval (CI) ϭ 14-32) and one in 50 could be saved from cardiovascular death (95% CI ϭ 32-111). Furthermore, one death (from total mortality causes) for every 63 treated patients could be prevented (95% CI ϭ 35-250). The data from the three trials restricted to persons with isolated systolic hypertension indicated a significant benefit; cardiovascular morbidity and mortality over approximately 5 years was reduced from 157 to 104 events per 1,000 participants (95% CI of the difference ϭ 12-89). The number of participants who dropped out of trials secondary to adverse drug effects was often not reported. The four trials that did report this data showed a wide variation in dropout rates ranging from no significant differences between treatment and control groups to as many as one out of four patients dropping out because of side effects of treatment.
CONCLUSIONS:
This meta-analysis demonstrates that treating hypertensive but otherwise healthy persons in their 60s and 70s is highly efficacious. The use of low-dose diuretics or beta-blockers is highly beneficial in treating diastolic or systolic hypertension. Cardiovascular benefits of treatment with a long-acting dihydropyridine calcium-channel blocker are clear for older people with isolated systolic hypertension. Differential treatment effects based on patients' preexisting cardiovascular disease, other comorbidities, and adverse drug effects could not be inferred from the study.
Five-year absolute morbidity and mortality benefits of antihypertensive therapy are greater for older than younger adults, but trials generally show benefits of antihypertensive treatment increase over time. Long-term cumulative benefits in younger persons with greater remaining life expectancy and fewer competing risks may exceed those in older persons.
COMMENTARY
This meta-analysis posed the question of the effectiveness of antihypertensive therapy in older people. Inclusion criteria for the selected randomized controlled trials were appropriate and corresponded to the aforementioned clinical query. The authors had conducted a thorough and exhaustive search of local and international databases, making it unlikely that other significant, relevant studies were missed. Treatment was randomized, and all subjects were accounted for at the end of each individual study. The two independent reviewers minimized random errors and bias, with disagreement resolved by discussion. A random effects model was used to combine outcomes across studies to ensure consistency. We are confident that the result of this meta-analysis is valid based on its meticulous statistical analysis.
This meta-analysis convincingly reaffirmed the effectiveness of antihypertensive therapy in the young old and middle old. Over 5 years, one in 19 treated patients could be saved from a cardiovascular morbidity and mortality event (95% CI ϭ 14-32) and one in 50 could be saved from a cardiovascular death (95% CI ϭ 32-111). Furthermore, one death (from total mortality causes) for every 63 treated patients could be prevented (95% CI ϭ 35-250).
Despite the overwhelming evidence of the effectiveness of pharmacotherapy, recent information on adverse effects of certain antihypertensive medications is not to be ignored. In the Studies of Left Ventricular Dysfunction trial, calcium-channel blocker use was found to be an independent predictor of myocardial infarction. 7 Whether a long-acting formulation is safer is yet to be determined by the completion of other trials. Another agent, doxazosin was prematurely pulled from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial because of the doubled risk of heart failure compared with chlorthalidone. 8 There were an adequate number of geriatric patients included in the meta-analysis. They were from industrialized countries, which are representative of the world's population at highest risk for the problem addressed. Nevertheless, in the U.S.-based trials, African Americans, who have the highest prevalence of hypertension in the nation, were relatively underrepresented 9 (Systolic Hypertension in the Elderly Program (SHEP) (14% African-American participants), SHEP Pilot Study (18% African-American participants), Veterans Administration Cooperative Study Group on Antihypertensive Agents (41% African-American participants), Hypertension Detection and Follow-up Program (49% African-American participants), and Hypertension-Stroke Cooperative Study Group (78% AfricanAmerican participants)). Fifty percent of the participants were female (they often outlive their male counterparts). The study population consisted mostly of independent, community-dwelling older people (with a small percentage,
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JUNE 2002-VOL. 50, NO. 6 JAGS 6%, from acute or long-term care institutions). Three trials that exclusively examined isolated systolic hypertension clearly showed the benefit of treating this high-risk group. Eleven of the 15 trials instituted a step-care approach. The average follow-up of 3 to 6 years was adequate. The percentage lost to follow-up of 5% in eight studies, 13% to 15% in three studies, and 25% in one study would be important to know but otherwise would have not affected the final result. Nevertheless, it would be helpful to have more data on dropouts due to adverse drug effects. Orthostatic hypotension, hyponatremia, dizziness, falls, and impotence are the common side effects that were not mentioned in the study, which could ultimately have deleterious effects on patient's quality of life. Despite the fact that it has been convincingly shown that treating hypertension in older people is beneficial, we still need data in assessing the efficacy of treating the frail, "oldest old" population ( Ͼ 85), which is the fastest growing segment of older people. With the pending results of the multimember randomized-controlled trial, Hypertension in the Very Elderly Trial, 10 which involves subjects aged 80 and older, it is hoped that we will soon have some answers. We also need further data to ascertain the effectiveness of treatment in patients with other comorbidities and residents of long-term care institutions.
Aside from the three trials (Randomized trial of treatment of hypertension in older patients in primary care, 1986; Medical Research Council Trial of Treatment of Hypertension in Older Adults, 1992; SHEP, 1991), which have shown no perceptible negative effect of treatment on measures of cognition, functional status, and mood, quality of life issues were overlooked in all the other trials. This should be examined in future research.
Recent studies have shown that pulse pressure could have a higher predictive value than systolic blood pressure with regard to total and cardiovascular-specific morbidity and mortality rates in older people [11] [12] [13] and thus is another area for confirmation in future research.
Finally, two practical issues of utmost importance that are not well elucidated in this review are cost and compliance. With the perennial problem of drug coverage, we should be aware of the most cost-effective treatment for a particular patient. To improve compliance, we should focus our educational efforts on improved quality of life rather than on mortality statistics, because it usually has a greater effect on older people and on their desire to have their blood pressure controlled.
Despite this excellent clinical verdict, we surmise that questions regarding optimization of treatment, especially in frail older people, remain.
